Current Partners


BIOVIA: The strategic content collaboration between BIOVIA (formerly Accelrys, now part of Dassault Systèmes) and Thomson Reuters accelerates innovation, speeds time-to-market and improves the competitiveness of pharmaceutical and biotech organizations. The integration delivers relevant, current and expertly curated life sciences content from Thomson Reuters Cortellis™ for Informatics via Pipeline Pilot, the scientifically-aware data integration, processing and reporting application, and via extensions into BIOVIA Enterprise Notebook and Insight..


CAMBRIDGE SEMANTICS: Joint customers are using Thomson Reuters content with Cambridge Semantics' Anzo software suite to create tailored competitive intelligence solutions either behind their firewalls or in a secure, private cloud. Anzo is a unified information access platform that lets companies combine data residing in their own databases, documents and spreadsheets with content from Thomson Reuters Cortellis and other public and proprietary 3rd-party sources. Anzo aggregates and harmonizes diverse data to produce curated and customized dashboards, analytics, alerts, and operational applications to solve specific business needs.


CERTARA: The integration between CERTARA and Thomson Reuters delivers expertly curated life sciences content from Thomson Reuters Cortellis, through the API's, directly into Certara's D360 solution platform. Additional information can be found at


DOTMATICS: The data analysis and visualization platform that has chemical structure intelligence, Vortex, can connect seamlessly to Thomson Reuters Cortellis content.  Vortex provides the plots and functionality required to explore and understand any complexity and size of data.  An easy-to-use graphical interface makes for easy data mash-up and analysis across all data types. By including Thomson Reuters data and their own proprietary data in Vortex, scientists can gain reliable insights to gain a competitive advantage.


GENOSPACE: Thomson Reuters will produce a curated database of genomic variation, with an emphasis on medical and scientific utility as part of their collaboration with GenoSpace. The aim of this partnership is to enable personalized medicine by providing hospitals, health systems, disease foundations and pharmaceutical research organizations with large scale clinical genomic data sets and tools. This solution will help in annotating and interpreting genomic variation and support better informed medical treatment decisions. GenoSpace produces a software platform and provides services for securely storing large volumes of genomic data.


IDBS: Thomson Reuters structured data can be accessed using IDBS's E–WorkBook — their electronic lab notebook offering. This connectivity makes it easier to combine Thomson Reuters data alongside the user's other internal sources, putting results into wider context. This avoids, cutting and pasting information, as it can now be moved directly into the experimental write up via ScienceLink. Researchers can bring whole reports and links to Thomson Reuters data into their electronic lab notebook.


INOVA: Thomson Reuters structured content can be accessed through Inova's platform. The incorporation of Thomson Reuters content into Inova's product helps customers enhance their ability to identify and acquire external innovations and develop partnerships. As a result, our mutual clients can make better informed decisions, generate innovation proposals that match requirements, and focus on where to find new innovation sources.


LINGUAMATICS: Linguamatics and Thomson Reuters have collaborated to create CortellisTM Informatics Clinical Text Analytics for I2E. The power of Linguamatics natural language processing (NLP) text analytics platform - I2E - is applied to Thomson Reuters Cortellis clinical and epidemiology content sets with literature, press releases and conference data in a secure, ready to use, on demand format. A single interface allows users to ask questions over the content and access new insights in support of trials, site selection and competitive intelligence to help them design more effective clinical trials and gain a deeper understanding of the implications of their results.